Sanofi and MIT to advance healthcare research
Fosters collaboration between academia and industry
Sanofi-aventis has agreed a partnership with the Massachusetts Institute of Technology (MIT) Centre for Biomedical Innovation to advance knowledge in the area of human health.
The partnership, which will be known as the Sanofi-aventis Biomedical Innovation Programme (SABIP), will promote scientific exchange between MIT and Sanofi-aventis and provide the French pharmaceutical firm with the opportunity to develop therapeutic, diagnostic and prognostic applications based on the discoveries made during the alliance.
The SABIP will allocate grants over the next three years to MIT researchers to enable them to develop potential healthcare solutions for patients.
‘Collaborations like SABIP that promote the exchange of scientific knowledge between academia and industry will play a key role,’ said Marc Cluzel, executive vice-president of r&d at Sanofi-aventis. ‘This alliance has the potential to provide innovative solutions to patients such as new drug delivery devices and technologies.’
Claude Canizares, vice president for research and associate provost at the Massachusetts Institute of Technology, added: ‘MIT brings strengths in advanced science and engineering relevant to healthcare and welcomes the opportunity to work with Sanofi-aventis on problems of common interest in biomanufacturing, nanotechnology and other areas.’